Skye Bioscience (Skye Bioscience) Cash per Share : $2.97 (As of Mar. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Skye Bioscience Cash per Share?

Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities divided by Shares Outstanding (EOP). Skye Bioscience's Cash per Share for the quarter that ended in Mar. 2024 was $2.97.

Skye Bioscience Cash per Share Historical Data

The historical data trend for Skye Bioscience's Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Skye Bioscience Cash per Share Chart

Skye Bioscience Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash per Share

Get a 7-Day Free Trial

2.50

2.14

4.72

0.34

0.10

Skye Bioscience Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cash per Share	Get a 7-Day Free Trial															0.69	0.14	0.42	0.10	2.97

Skye Bioscience Cash per Share Calculation

This is the ratio of a company's available cash, including easy to liquidate short-term investment, to its total number of shares outstanding. The result indicates the percentage of a company's share price that is available to spend on company's activities, such as strengthening the business, paying down the debt and making dividend payment to shareholders. It's a reliable indicator of a company's financial health.

Skye Bioscience's Cash per Share for the fiscal year that ended in Dec. 2023 is calculated as:

Cash per Share	=	Cash, Cash Equivalents, Marketable Securities	/	Shares Outstanding (EOP)
	=	1.256	/	12.35
	=	0.10

Skye Bioscience's Cash per Share for the quarter that ended in Mar. 2024 is calculated as:

Cash per Share	=	Cash, Cash Equivalents, Marketable Securities	/	Shares Outstanding (EOP)
	=	83.343	/	28.06
	=	2.97

Skye Bioscience (NAS:SKYE) Cash per Share Explanation

Cash per Share represents the liquidity of a compant's assets. A high level of Cash per Share suggests that there's enough money on hand for a company to cover any emergencies and that the company has adequate money to reinvest its business or pay dividends to investors. However, if the ratio is too high, it can also suggeust the inefficiency of management for not making a full usage of the cash.

Skye Bioscience Cash per Share Related Terms

Thank you for viewing the detailed overview of Skye Bioscience's Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Skye Bioscience (Skye Bioscience) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Skye Bioscience Inc (NAS:SKYE) » Definitions » Cash per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

11250 El Camino Real, Suite 100, San Diego, CA, USA, 92130

Website

https://www.skyebioscience.com

Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. It researches and develops and plans to commercialize cannabinoid derivatives through its own directed research efforts and through several license agreements with the University of Mississippi. The company's lead compound, SBI-100, is initially being developed to treat ocular disease.

Executives

Punit Dhillon	director	5820 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
John D Diekman	10 percent owner	C/O 5 AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
5am Partners Vii, Llc	10 percent owner	501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Paul A. Grayson	director	10578 SCIENCE CENTER DRIVE, SUITE 200, SAN DIEGO CA 92121
5am Ventures Vii, L.p.	10 percent owner	501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Kush Parmar	10 percent owner	C/O 5AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
5am Partners Ii, Llc	10 percent owner	501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
5am Co-investors Ii Lp	10 percent owner	501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Versant Ventures Iii, Llc	10 percent owner	ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Scott M Rocklage	10 percent owner	C/O 5AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Andrew J. Schwab	director, 10 percent owner	C/O 5AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Versant Side Fund Iii, L.p.	10 percent owner	ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
5am Ventures Ii Lp	10 percent owner	501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Versant Venture Capital Iii, L.p.	10 percent owner	ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Deborah H. Charych	director	1001 17TH ST, SAN FRANCISCO CA 94107